Bosentan for Treatment of Pediatric Idiopathic Pulmonary Arterial Hypertension: State-of-the-Art

被引：7
|
作者：
Wang, Yuchen [1 ,2 ]
Chen, Selena [3 ]
Du, Junbao [1 ,4 ]
机构：
[1] Peking Univ, Hosp 1, Dept Pediat, Beijing, Peoples R China
[2] Peking Univ, Hlth Sci Ctr, Dept Clin Med, Beijing, Peoples R China
[3] Univ Calif San Diego, Div Biol Sci, La Jolla, CA 92093 USA
[4] Minist Educ, Key Lab Mol Cardiovasc Sci, Beijing, Peoples R China
来源：
FRONTIERS IN PEDIATRICS | 2019年 / 7卷
基金：
北京市自然科学基金;
关键词：
idiopathic pulmonary hypertension; target therapy; bosentan; pediatrics; pharmacology; CHILDREN; THERAPY; SURVIVAL; SILDENAFIL; SAFETY; PHARMACOKINETICS; EPOPROSTENOL; FORMULATION; EXPRESSION; EXPERIENCE;
D O I：
10.3389/fped.2019.00302
中图分类号：
R72 [儿科学];
学科分类号：
100202 ;
摘要：
Idiopathic pulmonary arterial hypertension (IPAH) is a complex disease associated with progressive deterioration. Targeted therapy for IPAH has improved in the last several decades. However, there remain many challenges to current treatment of children with IPAH, including poor prognosis and a median survival of 0.8 years. Endothelin-1 (ET-1) appears to be a key mediator in the pathogenesis of IPAH, with elevated concentrations in the plasma. Bosentan, an endothelin receptor antagonist, has been confirmed in Food and Drug Administration (FDA) to effectively treat IPAH when administered in recent studies. This review focuses on related studies and advance of bosentan in the treatment of IPAH in children.
引用
收藏
页数：10
相关论文
共 50 条
  • [1] Bosentan in Pediatric Patients with Pulmonary Arterial Hypertension
    Beghetti, Maurice
    CURRENT VASCULAR PHARMACOLOGY, 2009, 7 (02) : 225 - 233
  • [2] Bosentan: In pediatric patients with pulmonary arterial hypertension
    Carter N.J.
    Keating G.M.
    Pediatric Drugs, 2010, 12 (1) : 63 - 73
  • [3] Bosentan for the treatment of pulmonary arterial hypertension
    Kenyon, KW
    Nappi, JM
    ANNALS OF PHARMACOTHERAPY, 2003, 37 (7-8) : 1055 - 1062
  • [4] Pulmonary arterial hypertension treatment with bosentan in pediatric patients with congenital heart disease
    Romero Jimenez, Rosa M.
    Garcia Sanchez, Raquel
    Gimenez Manzorro, Alvaro
    Martinez Fernandez-Llamazares, Cecilia
    Sanjurjo Saez, Maria
    PHARMACY WORLD & SCIENCE, 2009, 31 (02): : 347 - 347
  • [5] BUDGET IMPACT ANALYSIS OF BOSENTAN FOR TREATMENT OF PEDIATRIC PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION
    Soto Molina, H.
    Diaz-Alvarez, O.
    Sandoval-Avila, M.
    VALUE IN HEALTH, 2018, 21 : S58 - S58
  • [6] Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension
    Hoeper, MM
    Faulenbach, C
    Golpon, H
    Winkler, J
    Welte, T
    Niedermeyer, J
    EUROPEAN RESPIRATORY JOURNAL, 2004, 24 (06) : 1007 - 1010
  • [7] Endothelin receptor expression in idiopathic pulmonary arterial hypertension: effect of bosentan and epoprostenol treatment
    Hall, S. M.
    Davie, N.
    Klein, N.
    Haworth, S. G.
    EUROPEAN RESPIRATORY JOURNAL, 2011, 38 (04) : 851 - 860
  • [8] Long-term outcome of bosentan treatment in idiopathic pulmonary arterial hypertension and pulmonary arterial hypertension associated with the scleroderma spectrum of diseases
    Girgis, RE
    Mathai, SC
    Krishnan, JA
    Wigley, FM
    Hassoun, PM
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2005, 24 (10): : 1626 - 1631
  • [9] Bosentan. Role in the treatment of pulmonary arterial hypertension
    Carlos Grignola, Juan
    Gomez Sanchez, Miguel Angel
    INSUFICIENCIA CARDIACA, 2009, 4 (01) : 11 - 22
  • [10] Mildly symptomatic pulmonary arterial Hypertension Treatment with Bosentan?
    Halank, M.
    PNEUMOLOGE, 2009, 6 (01): : 35 - +
12345